1-11 of 11
Ann-Marie E. Bröske
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Jan Eckmann, Tanja Fauti, Marlene Biehl, Aintzane Zabaleta, Laura Blanco, Iva Lelios, Stefan Gottwald, Richard Rae, Stefanie Lechner, Christa Bayer, Quincy Dekempe, Franz Osl, Nadège Carrié, Sahar Kassem, Stefan Lorenz, Tony Christopeit, Alejandro Carpy, Alexander Bujotzek, Ann-Marie E. Bröske, Iryna Dekhtiarenko, Jan Attig, Leo Kunz, Floriana Cremasco, Roberto Adelfio, Georg Fertig, Stefan Dengl, Christian Gassner, Felix Bormann, Claudia Kirstenpfad, Thomas Emanuel Kraft, Sarah Diggelmann, Melanie Knobloch, Carina Hage, Romi Feddersen, Gordon Heidkamp, Thomas Pöschinger, Maud Lea Mayoux, Luise Bernasconi, Charles Dumontet, Felipe Prosper, Ludovic Martinet, Stephane Leclair, Wei Xu, Bruno Paiva, Christian Klein, Pablo Umaña
Journal: Blood
Blood blood.2024025987.
https://doi.org/10.1182/blood.2024025987
Published: 2024
Includes: Supplemental data
Journal Articles

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Sina Nassiri, Stephan Schmeing, Gabrielle Leclercq, Sylvia Herter, Llucia Alberti Servera, Tamara Hüsser, Emilio Yángüez, Diana Dunshee, Koorosh Korfi, Pablo Umana, Ann-Marie E. Bröske, Alessia Bottos, Marina Bacac
Journal: Blood
Blood (2023) 142 (Supplement 1): 1619.
https://doi.org/10.1182/blood-2023-179776
Published: 2023
Journal Articles

Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

Iryna Dekhtiarenko, Iva Lelios, Wolfgang Jacob, Meike Schneider, Martin Weisser, Carmelo Carlo-Stella, Salomon Manier, Simon J. Harrison, Rakesh Popat, Anna Caroline Hasselbalch Riley, Ann-Marie E. Bröske
Journal: Blood
Blood (2023) 142 (Supplement 1): 1948.
https://doi.org/10.1182/blood-2023-177669
Published: 2023
Journal Articles

CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89 Zr-Crefmirlimab Berdoxam

Martin Hutchings, Annika Loft, Wendy Osborne, George Petrides, Fritz Offner, Ciel De Vriendt, Giuseppe Gritti, Roberto Boni, William Townsend, Irfan Kayani, Ian Wilson, Yanjie Wang, Maria Jadhav, Cristina Santini, Claire Kelly, Martin Kornacker, Jean J.L. Tessier, Ann-Marie E Bröske, Angelika Lahr, Axel Boehnke, Christoph M. Griessinger
Journal: Blood
Blood (2022) 140 (Supplement 1): 10733–10735.
https://doi.org/10.1182/blood-2022-158154
Published: 2022
Journal Articles

Novel 17-Plex Flow Cytometry Assay for Comprehensive Immunophenotyping and Characterization of Plasma Cells (PC) in Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients

Iva Lelios, Enrique Gómez, Iryna Dekhtiarenko, Priscila Camillo Teixeira, Ann-Marie E Bröske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10714–10715.
https://doi.org/10.1182/blood-2022-162308
Published: 2022
Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E Bröske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Journal: Blood
Blood (2022) 140 (Supplement 1): 397–399.
https://doi.org/10.1182/blood-2022-157988
Published: 2022
Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Martin Hutchings, Caroline Hasselbalch Riley, Ann-Marie E Bröske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10137–10139.
https://doi.org/10.1182/blood-2022-158146
Published: 2022
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt
Journal: Blood
Blood (2019) 134 (Supplement_1): 2871.
https://doi.org/10.1182/blood-2019-123978
Published: 2019
Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3799.
https://doi.org/10.1182/blood-2019-123712
Published: 2019
Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Ann-Marie E Bröske, PhD, Ian James, PhD, Anton Belousov, PhD, Enrique Gomez, PhD, Marta Canamero, MD PhD, Chia-Huey Ooi, PhD, Nils Grabole, PhD, Sabine Wilson, PhD, Koorosh Korfi, PhD, Nicole A Kratochwil, PhD, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Denise Thomas, MSc, Natalie Dimier, PhD, Tom Moore, MBChB, Marina Bacac, PhD, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5319.
https://doi.org/10.1182/blood-2019-123979
Published: 2019
Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1584.
https://doi.org/10.1182/blood-2019-123949
Published: 2019